Lipfendra vs Repatha: Unless You Absolutely Hate Needles, Stick With the Shot

The new pill saves you the injection. It costs you a fasting window every morning, and a price nobody can quote you yet.

I am not the guy either of these drugs is for. My LDL is 56 and my ApoB is 59, I take no statin, and my calcium score is zero. I got there on tirzepatide, weight loss, and a generic pill that costs about a dollar a day.

But since the FDA approved Lipfendra (enlicitide) on July 16, 2026, the question I keep seeing is the obvious one. There is now a pill that does what the injection does, so why would anyone keep injecting?

The short answer

Lipfendra and Repatha are not the same drug. Both block PCSK9, both cut LDL by roughly the same amount, and both are add-ons to a statin you can tolerate rather than replacements for one. Repatha is an injected antibody you can pick up this week. Lipfendra is a daily tablet that reaches pharmacies in early 2027.

Unless you genuinely hate needles, stick with Repatha for now. It is available today, and for most insured people it is cheap. Lipfendra spares you the injection, but it asks for a fasting window every single morning, and its only published price is a list price that does not undercut what people actually pay for Repatha. Wait until it launches and we can see real prices.

Repatha is here today, and cheaper than the headlines suggest

The launch coverage led with Lipfendra’s list price of $315 a month, about $3,780 a year, and framed it as the aggressive number because it sits below the conventional list prices of the injections. That comparison only works if you assume people pay list for the injection. They mostly do not.

An eligible commercially insured patient can pay as little as $25 a month for Repatha with the manufacturer’s copay card. Someone paying cash without insurance is quoted $239 a month through AmgenNow, which Amgen describes as roughly 60% below its own list.

Sit those next to each other and the headline inverts. Repatha’s cash price, the one you pay with no insurance at all, is lower than Lipfendra’s list price. The new pill is not the budget option here. It is the most expensive number on the board and the only one you cannot buy yet.

Two honest caveats. Repatha’s list price is higher than $315, so on a pure list-to-list basis Merck did undercut Amgen. And Lipfendra has not launched, so it has no copay card and no cash program yet. Its list is the only number it has. That is exactly why I would not commit to it today.

What is the catch with Lipfendra?

The pill is not simply a pill. Lipfendra’s label has you take the tablet in the morning on an empty stomach, then wait 30 minutes before eating or drinking anything other than water, black coffee, or plain tea. Every day.

That is more forgiving than it first sounds, and I want to be fair to it. Black coffee is allowed, which matters to most men I know. The label also says it can be taken alongside other medicines, and an interaction study found no meaningful effect when it was given with oral semaglutide, so this is not a drug that fights with your existing prescriptions.

But it is still a fasting window bolted onto the start of every day, indefinitely. Set that against an injection every two weeks or once a month. For plenty of people the pill is obviously easier. If you already take a thyroid tablet, which wants the same empty stomach, it is not easier at all. Daily dosing also gives you 365 chances a year to forget, against 12 to 26.

That cuts both ways, and here is the part that genuinely favours the pill. A lot of people handed a prescription for an injectable PCSK9 inhibitor never end up taking one. In a study of more than 45,000 Americans prescribed evolocumab or alirocumab during the drugs’ first year on the market, only 47.2% got insurance approval, and 34.7% of the approved prescriptions were never filled. Abandonment ran above 75% once the copay cleared $350. That was 2015 and 2016, when list prices were far higher, and access has improved a great deal since. A trial will not show you that problem either. Adherence in CORALreef Lipids ran about 97%, with the reminders and monitoring that come with being in a study. Nobody is reminding you at year two.

So if you are someone who will not inject, and I mean genuinely will not, to the point where the honest alternative is taking nothing, then the pill is a real option and worth waiting for. Just do not leave a high ApoB untreated for eighteen months while you wait. Ask your doctor what you can take now.

What are the side effects?

Neither drug has an alarming safety profile, and that is worth saying plainly, because it means tolerability is not what decides this one.

In Lipfendra’s trials the safety picture was close to placebo overall, with somewhat more diarrhea, 7 percent against 2 percent, and more dizziness, 9 percent against 4 percent, in the heterozygous familial hypercholesterolemia study.

Repatha has much the longer record. In FOURIER, across 27,564 people, there was no significant difference in adverse events against placebo, including new-onset diabetes and neurocognitive effects, which were the two things people worried about when this class first drove LDL down into the 30s. The one exception was injection-site reactions, at 2.1 percent against 1.6 percent.

So both are well tolerated, and the practical difference is a mild gut and dizziness signal on one side against a small chance of a sore injection site on the other. The asymmetry that matters is length of record rather than severity. Lipfendra’s main safety data runs to 24 weeks. Repatha has years of follow-up in tens of thousands of people.

How much does Lipfendra cost compared with Repatha?

	Lipfendra (enlicitide)	Repatha (evolocumab)
Route	Oral, once daily, empty stomach	Injection, every 2 weeks or monthly
LDL reduction	~56% (CORALreef Lipids)	~59% (FOURIER)
List price	$315/month (~$3,780/yr)	~$490/month
Commercial copay card	Does not exist yet	As little as $25/month if eligible
Cash price	Does not exist yet	$239/month via AmgenNow
Outcomes data	Not yet; primary completion Nov 2029	Yes, FOURIER and VESALIUS-CV
Available now?	No, early 2027	Yes

The two LDL figures come from different trials in different populations. No head-to-head trial exists, so read them as the same neighbourhood rather than a ranking.

On Medicare the picture is worse for the pill, for a reason that catches people. Federal law bars manufacturer copay cards for anyone on Medicare or Medicaid, so the $25 figure is commercial insurance only. Lipfendra also will not reach a Part D formulary until the 2027 plan year at the earliest. I went through when Medicare is likely to start covering Lipfendra separately.

What about the heart-attack evidence?

This is the part most coverage leads with, and I think it deserves less weight than it gets.

Repatha has finished the trials. In FOURIER, 27,564 people with established cardiovascular disease saw the primary composite endpoint drop from 11.3% to 9.8%, a hazard ratio of 0.85. A prespecified analysis looked at heart attacks specifically and found first myocardial infarction fell from 6.3% to 4.4%, a hazard ratio of 0.73. VESALIUS-CV then tested it in 7,557 people who had atherosclerosis or high-risk diabetes but no previous heart attack or stroke, and found a number needed to treat of 28 to 40 over five years to prevent one major coronary event.

Lipfendra’s outcomes trial, CORALreef Outcomes, enrolled 14,550 people and is still running. Primary completion is scheduled for November 2029, and that is when data collection ends rather than when results appear.

I do not think that gap should decide this for you, though. LDL lowering is about the most reliable surrogate in all of cardiology, Lipfendra hits the same target by the same mechanism, and it cuts ApoB by roughly half. The reasonable expectation is that it reduces events. Biologically plausible, not yet demonstrated. If you are already at high risk and starting a drug this month, I would still take the one with the finished trials, but that is a tiebreaker, not the reason to choose.

Already on Repatha? Should you switch?

If Repatha is working, you tolerate it, and it is covered, stay where you are. Nothing here makes switching to an unlaunched drug with an unknown price a good trade.

If you are skipping doses because of the needle, or you have quietly stopped, that is a different conversation and it is worth having with your doctor in 2027, when the pill is actually on the shelf and priced.

Is Lipfendra better than Repatha?

It is better if what you mean is that you would rather swallow something than inject it. That is a real advantage and I am not going to talk anyone out of it.

On everything else, not yet. It asks for a fasting window every morning. Its only published price is higher than what most people pay for Repatha. It is not in pharmacies until early 2027, and not on Medicare until the 2027 plan year at the earliest. And nobody, including Merck, can currently tell you what it will cost you at the counter.

If you are at or near your LDL and ApoB goal on generics, none of this is your next move anyway. A statin, ezetimibe, or both rarely run more than about a dollar a day and get a large share of people where they need to be. That is the group I am in. If you do not know your ApoB, getting that number is a better use of your next appointment than either of these drugs, and I wrote a plain-English guide to reading the panel.

And if you do need PCSK9-level lowering, whether from genuine statin intolerance, heterozygous familial hypercholesterolemia, or an ApoB that will not come down any other way, the drug to ask your doctor about this month is the one you can actually get. Then watch what Lipfendra costs once it launches, and revisit it with a real number in front of you.